ERBB2 and cancer: Compared to MG, US could detect more invasive NPBC (83.6% vs 54.3%, p<0.001), lymph node positive cancer (19.1% vs 10.2%, p=0.018), low grade cancer (24.8% vs 16.5%, p<0.001), multifocal cancer (19.2% vs 6.3%, p<0.001), PR positive cancer (71.4% vs 66.9%, p=0.041), Her2 negative cancer (74.3% vs 54.3%, p<0.001), Ki67 high cancer (defined as >14%, 46.3% vs 37.0%, p=0.031) and more NPBC which needed chemotherapy (40.7% vs 21.3%, p<0.001).